Global Aquablation Therapy Market Strategic Research Report

Scope of the Report

The global Aquablation Therapy market size is predicted to grow from US$ 2,078 million in 2025 to US$ 4,252 million in 2032; it is expected to grow at a CAGR of 10.7% from 2026 to 2032.

Aquablation therapy is a transurethral, minimally invasive approach for treating lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). It combines real-time transrectal ultrasound (TRUS) imaging for anatomical mapping and resection planning with robotic execution of a high-velocity sterile saline waterjet that cuts and removes obstructive prostate tissue within a predefined treatment zone. Unlike thermal modalities (electrocautery/laser), Aquablation is positioned as a heat-free, image-guided, robot-assisted workflow designed to improve reproducibility and reduce variability associated with thermal injury.The average gross profit margin of this product is 35%.

Aquablation sits at the intersection of two powerful trends: minimally invasive BPH surgery and surgical robotics. Regulators and evidence frameworks clearly define its intended use and technical pathway—transurethral, image-guided (TRUS) robotic execution of a high-velocity sterile saline waterjet for prostate tissue removal—supporting standardized pathway building in hospitals. Reimbursement mechanics are also becoming more predictable: Aquablation has been granted a Category I CPT code effective January 1, 2026, helping translate an innovative technique into more manageable coding and hospital pathway planning. Internationally, NICE guidance states transurethral water-jet ablation may be used with standard arrangements for governance, consent, and audit—reinforcing compliant, repeatable adoption.

Scaling is constrained less by the concept and more by platform economics and workflow change. Aquablation requires capital equipment, intraoperative TRUS integration, and team training—forcing hospitals to balance budgets, OR capacity, and learning curves. Meanwhile, BPH surgery is intensely competitive, with TURP, HoLEP, thermal ablation options, and implant-based approaches embedded in existing practice and procurement. Coverage and positioning can still vary across payers and geographies, so adoption often hinges on aligning clinical evidence, cost structure, and pathway efficiency into a coherent value proposition.

Demand is shifting from “choosing a procedure” to “choosing outcomes and experience.” Providers increasingly focus on predictable symptom relief, recovery pathways, and durability, integrating Aquablation into standardized perioperative care. A growing clinical evidence base—including durability signals in larger glands—supports broader applicability and routine stocking beyond early-adopter centers. With Category I CPT now effective and guideline/payer positions becoming clearer, diffusion is likely to expand from high-volume centers toward regional hospitals and ambulatory pathways, following a familiar curve of capital placement, consumable growth, and standardized training/follow-up.

Upstream structure is a hybrid chain of capital equipment, single-use procedural components, and sterile fluidics. The platform includes a high-pressure pump and fluid control, robotic actuation, endoscopic visualization, TRUS-related hardware, and planning software; disposables cover handpiece/tubing sets, seals/connectors, medical-grade polymers and metals, sterile packaging, and validated sterilization—using sterile saline as the cutting medium. Because performance is highly sensitive to fluid stability, device consistency, and sterility assurance, supplier capability in precision fluidic manufacturing, traceability, assembly reproducibility, software/hardware reliability, and end-to-end quality systems directly shapes OR efficiency, failure risk, and long-term reputation.

This report presents a comprehensive overview of the global Aquablation Therapy market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Aquablation Consoles
• Single-use Handpieces
• Imaging & Planning Software

Segment by Anesthesia Type

• General Anesthesia
• Spinal Anesthesia
• Other

Segment by Site of Care

• Inpatient OR
• Ambulatory Surgery Center
• Other

Segment by Application

• Benign Prostatic Hyperplasia (BPH)
• Prostate Tissue Debulking
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Aquablation Therapy market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Benign Prostatic Hyperplasia (BPH), Prostate Tissue Debulking, Other evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact